TW200602040A - Method of treating schizophrenia and/or glucoregulatory abnormalities - Google Patents

Method of treating schizophrenia and/or glucoregulatory abnormalities

Info

Publication number
TW200602040A
TW200602040A TW094110410A TW94110410A TW200602040A TW 200602040 A TW200602040 A TW 200602040A TW 094110410 A TW094110410 A TW 094110410A TW 94110410 A TW94110410 A TW 94110410A TW 200602040 A TW200602040 A TW 200602040A
Authority
TW
Taiwan
Prior art keywords
c6alkyl
halogen
hydrogen
independently hydrogen
treating schizophrenia
Prior art date
Application number
TW094110410A
Other languages
English (en)
Inventor
Craig P Smith
David E Rampe
Beth Borowsky
Sathapana Kongsamut
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of TW200602040A publication Critical patent/TW200602040A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW094110410A 2004-04-01 2005-04-01 Method of treating schizophrenia and/or glucoregulatory abnormalities TW200602040A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55845104P 2004-04-01 2004-04-01

Publications (1)

Publication Number Publication Date
TW200602040A true TW200602040A (en) 2006-01-16

Family

ID=34978926

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094110410A TW200602040A (en) 2004-04-01 2005-04-01 Method of treating schizophrenia and/or glucoregulatory abnormalities

Country Status (26)

Country Link
US (1) US20070129403A1 (zh)
EP (2) EP2138176A1 (zh)
JP (1) JP2007531730A (zh)
KR (1) KR20070010161A (zh)
CN (1) CN1946399A (zh)
AR (1) AR048197A1 (zh)
AT (1) ATE446754T1 (zh)
AU (1) AU2005231446A1 (zh)
BR (1) BRPI0509512A (zh)
CA (1) CA2561162A1 (zh)
CL (1) CL2009001605A1 (zh)
CY (1) CY1109734T1 (zh)
DE (1) DE602005017373D1 (zh)
DK (1) DK1734959T3 (zh)
DO (1) DOP2005000050A (zh)
ES (1) ES2334241T3 (zh)
GT (1) GT200500063A (zh)
IL (1) IL178168A0 (zh)
MX (1) MXPA06011222A (zh)
PA (1) PA8628601A1 (zh)
PL (1) PL1734959T3 (zh)
PT (1) PT1734959E (zh)
SI (1) SI1734959T1 (zh)
SV (1) SV2006002069A (zh)
TW (1) TW200602040A (zh)
WO (1) WO2005097122A2 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
CN103271906A (zh) 2006-10-12 2013-09-04 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
NZ592275A (en) 2008-10-17 2013-04-26 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010068750A2 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
CA2760825C (en) * 2009-06-03 2017-07-11 Marquette University Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MY165579A (en) 2009-10-14 2018-04-05 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
CN105726531A (zh) 2010-02-26 2016-07-06 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
CN103512972A (zh) * 2013-07-29 2014-01-15 上海交通大学 精神分裂症的生物标志物及其使用方法和应用
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
KR101759122B1 (ko) 2015-08-07 2017-07-18 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
WO2020188051A1 (en) * 2019-03-19 2020-09-24 Cambridge Cognition Limited Method and uses of diagnosing and recommending treatment for a psychotic disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970218A (en) 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
EP0287982B1 (en) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US5102891A (en) * 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder
MX9800774A (es) * 1995-07-27 1998-04-30 Hoechst Marion Roussel Inc Uso de n-(pirrol-1-il)piridinaminas no sustituidas y sustituidas como agentes anticonvulsivos.
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
PL1734959T3 (pl) 2010-03-31
CA2561162A1 (en) 2005-10-20
EP2138176A1 (en) 2009-12-30
CN1946399A (zh) 2007-04-11
DK1734959T3 (da) 2010-03-08
DOP2005000050A (es) 2005-11-30
WO2005097122A2 (en) 2005-10-20
JP2007531730A (ja) 2007-11-08
CY1109734T1 (el) 2014-09-10
DE602005017373D1 (de) 2009-12-10
GT200500063A (es) 2005-10-14
US20070129403A1 (en) 2007-06-07
MXPA06011222A (es) 2007-01-16
SV2006002069A (es) 2006-05-24
EP1734959B1 (en) 2009-10-28
AU2005231446A1 (en) 2005-10-20
BRPI0509512A (pt) 2007-09-11
CL2009001605A1 (es) 2009-11-27
PA8628601A1 (es) 2006-05-16
KR20070010161A (ko) 2007-01-22
ES2334241T3 (es) 2010-03-08
ATE446754T1 (de) 2009-11-15
IL178168A0 (en) 2006-12-31
SI1734959T1 (sl) 2010-02-26
AR048197A1 (es) 2006-04-05
EP1734959A2 (en) 2006-12-27
PT1734959E (pt) 2009-12-24
WO2005097122A3 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
TW200602040A (en) Method of treating schizophrenia and/or glucoregulatory abnormalities
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
WO2007112000A3 (en) Treatment of pain
TW200639159A (en) Treatment of pain
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
CA2405796A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
TW200508180A (en) Therapeutic agents
IL189546A0 (en) Therapy for the treatment of disease
TW200642685A (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
GB0112348D0 (en) Compounds
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
WO2005056524A3 (en) Therapeutic agents useful for treating pain
WO2007056264A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
CL2004001050A1 (es) Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
DK2040703T3 (da) Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf
BRPI0405657A (pt) Método para o tratamento de insuficiência cardìaca grave e medicamento para o mesmo
MXPA05012392A (es) Tratamientos de ansiedad con ziprasidona.
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
EA200970424A1 (ru) Способы лечения кохлеарных и вестибулярных нарушений
SE0004101D0 (sv) New use